NCT02558816 - A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 14, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

May 13, 2025

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Ibrutinib + GA101 +GDC-0199

Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199

Trial Locations (9)

21000

CHU de Dijon, Dijon

33604

Hôpital du Haut Lévêque, Pessac

34295

Hôpital Saint Eloi, Montpellier

35033

CHU Rennes, Rennes

44093

CHU de Nantes, Nantes

49033

CHU Angers, Angers

59037

Hôpital Claude Huriez - CHRU de Lille, Lille

PL6 8DH

Derriford Hospital _ Plymouth Hospitals NHS Trust, Plymouth

SO16 6YD

University of Southampton, Southampton

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

collaborator

Roche Pharma AG

INDUSTRY

lead

Nantes University Hospital

OTHER